1
|
Hladun O, Papaseit E, Martín S, Barriocanal AM, Poyatos L, Farré M, Pérez-Mañá C. Interaction of Energy Drinks with Prescription Medication and Drugs of Abuse. Pharmaceutics 2021; 13:pharmaceutics13101532. [PMID: 34683828 PMCID: PMC8541613 DOI: 10.3390/pharmaceutics13101532] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 09/17/2021] [Accepted: 09/18/2021] [Indexed: 11/16/2022] Open
Abstract
In recent years, the consumption of energy drinks (EDs) has become increasingly popular, especially among adolescents. Caffeine, a psychostimulant, is the main compound of EDs which also contain other substances with pharmacological effects. This review aims to compile current evidence concerning the potential interactions between EDs, medicines, and drugs of abuse as they are frequently consumed in combination. The substances involved are mainly substrates, inductors or inhibitors of CYP1A2, psychostimulants, alcohol and other depressant drugs. Furthermore, intoxications reported with EDs and other substances have also been screened to describe acute toxicity. The results of our review show that the consumption of both EDs alone and in combination is not as safe as previously thought. Health professionals and consumers need to be aware of the potential interactions of these drinks as well as the absence of long-term safety data.
Collapse
Affiliation(s)
- Olga Hladun
- Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain; (O.H.); (S.M.); (A.M.B.); (L.P.); (M.F.); (C.P.-M.)
- Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain
| | - Esther Papaseit
- Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain; (O.H.); (S.M.); (A.M.B.); (L.P.); (M.F.); (C.P.-M.)
- Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain
- Correspondence: ; Tel.: +34-934978843
| | - Soraya Martín
- Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain; (O.H.); (S.M.); (A.M.B.); (L.P.); (M.F.); (C.P.-M.)
| | - Ana Maria Barriocanal
- Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain; (O.H.); (S.M.); (A.M.B.); (L.P.); (M.F.); (C.P.-M.)
- Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain
| | - Lourdes Poyatos
- Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain; (O.H.); (S.M.); (A.M.B.); (L.P.); (M.F.); (C.P.-M.)
- Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain
| | - Magí Farré
- Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain; (O.H.); (S.M.); (A.M.B.); (L.P.); (M.F.); (C.P.-M.)
- Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain
| | - Clara Pérez-Mañá
- Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain; (O.H.); (S.M.); (A.M.B.); (L.P.); (M.F.); (C.P.-M.)
- Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain
| |
Collapse
|
2
|
Alkadhi KA. Long-term potentiation in autonomic ganglia: Potential role in cardiovascular disorders. World J Pharmacol 2016; 5:51-58. [DOI: 10.5497/wjp.v5.i2.51] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2016] [Accepted: 07/13/2016] [Indexed: 02/06/2023] Open
Abstract
Ganglionic long-term potentiation (gLTP) is an activity-dependent, enduring enhancement of ganglionic transmission. This phenomenon may be induced in autonomic ganglia of an organism under certain conditions where repetitive impulses surge from the central nervous system (CNS) to the periphery. Chronic stress, repetitive epileptic seizure or chronic use of CNS stimulants could induce gLTP, which would result in a long lasting heightening of sympathetic tone to the cardiovascular system causing hypertension and disturbed cardiac rhythm that may lead to sudden cardiac death. These conditions are briefly reviewed in this article.
Collapse
|